Abstract
mTOR/p70S6K pathway is considered a central regulator in various malignant tumors, but its roles in esophageal squamous cell carcinoma (ESCC), which is a common cause of mortality in China, remain unknown. Here, we identify that the mTOR/p70S6K pathway is activated in ESCC; rapamycin and siRNA against mTOR rapidly inhibited expression of mTOR and the phosphorylation of its major downstream effectors, p70S6K and 4E-BP1, arrested cells in the G(0)/G(1) phase and induced apoptosis of ESCC cells. The findings may lay a foundation for making further investigations on the mTOR/p70S6K pathway as a potential target for ESCC therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibiotics, Antineoplastic / pharmacology*
-
Carcinoma, Squamous Cell / enzymology*
-
Carcinoma, Squamous Cell / genetics
-
Cell Cycle / drug effects
-
Cell Line, Tumor
-
Cell Proliferation
-
Esophageal Neoplasms / enzymology*
-
Esophageal Neoplasms / genetics
-
Humans
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinases / drug effects*
-
Protein Kinases / genetics
-
Protein Kinases / metabolism
-
RNA, Small Interfering / pharmacology*
-
Ribosomal Protein S6 Kinases, 70-kDa / antagonists & inhibitors*
-
Ribosomal Protein S6 Kinases, 70-kDa / genetics
-
Ribosomal Protein S6 Kinases, 70-kDa / metabolism
-
Signal Transduction / drug effects
-
Sirolimus / pharmacology*
-
TOR Serine-Threonine Kinases
-
Transfection
-
Up-Regulation / drug effects
Substances
-
Antibiotics, Antineoplastic
-
Protein Kinase Inhibitors
-
RNA, Small Interfering
-
Protein Kinases
-
MTOR protein, human
-
Ribosomal Protein S6 Kinases, 70-kDa
-
TOR Serine-Threonine Kinases
-
Sirolimus